- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: HB12  | inebilizumab-cdon | MEDI 551 | MEDI-551 | MEDI551 | Uplizna®
inebilizumab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Inebilizumab is a humanized monoclonal antibody (mAb) directed against CD19, a cell-surface antigen expressed on cells of B cell lineage. Inebilizumab has potential immunomodulating and antineoplastic activities. Tested preclinically as a mouse anti-CD19 mAb (clone HB12; ), and initially humanized by Cellective Therapeutics, Inc. (a spinout company from Duke University where the antibody began its life) prior to being acquired by MedImmune (now part of Astra Zeneca) for commercial development.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A protein BLAST search of patented sequences reveals 100% matches between the heavy and light variable sequences of inebilizumab and sequences 106 and 111 respectively, in patent US8323653 B2 . A detailed peptide sequence analysis suggests that inebilizumab is likely to be clone 16C4 in this patent.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Damschroder M, Kiener P, Wu H, Dall'Acqua W, Herbst R, Coyle A. (2012)
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease.
Patent number: US8323653 B2. Assignee: Medimmune, Llc. Priority date: 08/09/2006. Publication date: 04/12/2012.
2. Forero-Torres A, Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, Verhoef G, Federico M, Gregory GA, Sonet A et al.. (2013)
Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies.
Blood, 122 (21): 1810 Meeting poster. DOI: 10.1182/blood.V122.21.1810.1810
3. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K et al.. (2010)
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
J. Pharmacol. Exp. Ther., 335 (1): 213-22. [PMID:20605905]
4. Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter SS, Wilson BS. (2013)
Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.
Leukemia, 27 (6): 1263-74. [PMID:23307031]
5. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H et al.. (2011)
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Br. J. Haematol., 155 (4): 426-37. [PMID:21902688]
6. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. (2005)
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
Proc. Natl. Acad. Sci. U.S.A., 102 (42): 15178-83. [PMID:16217038]